The company sold over 21 crore (210 million) shares in Sun Pharma.
The health ministry has formed a committee to consider raising the number of drugs deemed essential and subject to price caps.
Sun Pharmaceutical said Ranbaxy shareholders will get 0.8 Sun Pharma shares for each Ranbaxy share.
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had filed an application with the US Food and Drug Administration to market a generic form of GlaxoSmithKline's anti-nausea drug Zofran.\n\n
Roche has already adapted its business model in India to increase affordable access to drugs and try to stave off trouble from India's patent authorities.
The move follows an FDA inspection of a Ranbaxy facility which identified significant violations of sound manufacturing practices.
Some US doctors are becoming concerned about the quality of generic drugs supplied by Indian manufacturers following a flurry of recalls and import bans by the Food and Drug Administration.
Indian drugmakers' domestic sales of ready-to-take medicines in January-March could be lower than expected as distributors suspended stocking in anticipation of a new value-added tax system coming into force, analysts and industry members said.\n\n\n\n
Industry fears tougher US stance on IP after President Donald Trump asserted that foreign countries must pay a fair share for drug development costs. Aneesh Phadnis reports.
The investment has lost almost 40 percent of its value in six years.
The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment into India.
The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas in India and included acne drug Sotret, epilepsy and nerve pain drug gabapentin and antibiotic ciprofloxacin.
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
Sector observers refute, call response a bluff.
It is one of 42 drug-making factories in India that the FDA has banned in recent years
Firm pleads guilty to lying to US FDA; says it had set aside the money.
Supreme Court will give its verdict on April 1 on whether Swiss giant Novartis AG's cancer treatment drug Glivec deserves a patent in the country not it doesn't.
India had the third-largest number of people living with HIV in the world at the end of 2013 and accounts for about four out of 10 people living with HIV in the Asian region.
The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.
Fabiflu sales have grown by 62 per cent in July. It was launched in June. This drug is being used by doctors for mild-to-moderate Covid patients even if they are in home isolation.
US Department of Justice had charged Wyeth for promoting its acid reflux drug Protonix for unapproved uses and making unproven claims.
The deal would involve Pfizer paying with 11.3 of its shares for each Allergan share.
Piramal owns an 11 per cent stake in Vodafone India.
Investors have stepped up ploughing money into the healthcare sector in India.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Adani Power will also be dropped from the S&P BSE 100 index
Some critics contend that Japan's rush to secure supplies is driven largely by a political desire to show the world it is fully committed to hosting the Games.
US-based drugmaker Pfizer and Indian biotechnology major Bicon today said they have agreed to end their alliance to sell insulin and insulin analog products made by the Indian company.
Drugmaker Aurobindo Pharma on Monday said it has entered into licensing and supply agreements with London-based pharmaceutical giant AstraZeneca to supply several solid dosage and sterile products for emerging markets.
Sources say FDA letter over product and not entire facility
Beleaguered drugmaker Wockhardt has a new management team in place to implement a three-year strategic plan to get back on track. The company has seen at least four senior-level exits in the last few months.
India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday.
This week, global drugmakers Pfizer and BioNTech said their COVID-19 vaccine candidate is 95 per cent effective, including in adults over 65 years of age.
IPA had said many of the patent claims made by multinationals do not necessarily enhance the efficacy of previously known drugs.
The company has received a tentative approval for the company's abbreviated new drug application for Eszopiclone tablets from the US Food and Drug Administration, Lupin said in a filing to the Bombay Stock Exchange.
Sun Pharmaceutical Industries and its subsidiary, Caraco Pharmaceutical Laboratories, have reached a settlement agreement with drugmaker Forest Laboratories and licensing partner H Lundbeck AS, over a pending patent infringement dispute over Forest's blockbuster antidepressant, Lexapro.
The finance ministry is resisting pressure from other departments to cap foreign ownership of domestic drugmakers, fearing such a move would discourage potential investors, a senior ministry source said.
The Drug Controller General of India has sent a letter to the Glenmark seeking clarifications on pricing as well as claims of therapeutic efficacy. While Glenmark has claimed this drug is effective in comorbid conditions like diabetes, hypertension, according to protocol summary (of clinical trials) the trial was not designed to access the Fabiflu in comorbid conditions.
In many cases, of course, financial institutions like Life Insurance Corporation or government-controlled banks have come to the rescue of Indian companies facing takeover threats.
